Surge in Tamiflu sales drive Roche's first half
This article was originally published in Scrip
Executive Summary
Roche's first-half pharmaceutical sales rose by 11% to CHF19.1 billion ($17.9 billion) as global sales of its flu treatment Tamiflu (oseltamivir) surged in the second quarter.